Clinical Trials

Seattle Genetics, Inc. is conducting clinical trials of the following four antibody-based product candidates. If you have questions about our ongoing clinical trials, please email Seattle Genetics at clinicaltrials@seagen.com.

SGN-40 (under worldwide collaboration agreement with Genentech)

• Diffuse Large B-Cell Lymphoma (single agent phase II)

• Diffuse Large B-Cell Lymphoma (randomized phase IIb)
• Diffuse Large B-Cell Lymphoma (combination phase Ib)
• Indolent Non-Hodgkin Lymphoma (combination phase Ib)

• Multiple Myeloma (Revlimid combination phase Ib)

• Multiple Myeloma (Velcade combination phase Ib)

SGN-33 (lintuzumab)

• AML (combination phase IIb)

• AML and MDS (single agent phase Ib)

• MDS (combination phase I)
   

SGN-35 (antibody-drug conjugate)

• Hodgkin lymphoma and other CD30-positive hematologic malignancies (single agent, every three week schedule phase I)

• Hodgkin lymphoma and other CD30-positive hematologic malignancies (single agent, weekly schedule phase I)

SGN-70

• Healthy volunteers (phase I)

About Cancer Therapies

Cancer is the second leading cause of death for people in the United States, resulting in over 565,000 deaths annually. Current cancer treatments include surgery, radiation, chemotherapy, hormones and immunotherapy. Therapies for advanced stage or metastatic cancer continue to fall short of extending survival for the majority of patients. While response rates of 50% or more can be seen with newer anti-cancer agents, time to disease progression and overall survival have not been dramatically improved in most cases. Consequently, continued effort to develop new treatments and combinations is needed to improve the disease-free and overall survival for cancer patients.

In the last decade, a number of new agents with promising antitumor activity have been developed. These include monoclonal antibodies, a class of biologic agent, which can target tumors and potentially limit the toxicity to normal tissues associated with traditional chemotherapy.